Alembic Pharmaceuticals receives USFDA’s final approval for Pantoprazole Sodium Injection

01 Apr 2025 Evaluate

Alembic Pharmaceuticals has received Final Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Pantoprazole Sodium for Injection, 40 mg/vial (Single-Dose Vial). Alembic has a cumulative total of 221 ANDA approvals (195 final approvals and 26 tentative approvals) from USFDA.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Protonix I.V. for Injection, 40 mg/vial, of Wyeth Pharmaceuticals LLC. Pantoprazole sodium for injection is indicated for treatment of gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults. It is also indicated for the treatment of pathological hypersecretion conditions including Zollinger-Ellison (ZE) Syndrome in adults. 

Alembic Pharmaceuticals is principally engaged in the manufacturing and selling of pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients.



Alembic Pharma Share Price

769.05 7.30 (0.96%)
22-Jan-2026 15:13 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1633.55
Dr. Reddys Lab 1215.50
Cipla 1369.45
Zydus Lifesciences 885.15
Lupin 2164.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×